Status:
COMPLETED
Effect of Intralymphatic Immunotherapy
Lead Sponsor:
University of Aarhus
Conditions:
Allergy
Immune Tolerance
Eligibility:
All Genders
18-40 years
Phase:
PHASE2
Brief Summary
The investigators want to investigate whether specific immunotherapy can be delivered directly into a lymph node. The investigators think that a direct introduction of allergen to the antigen presenti...
Detailed Description
Patients are injected with 3 or 4 doses of alk 225 Phleum Pratense 1000 standard quantity units/ml in a lymph node in the groin. The investigators monitor clinical response and use of medication duri...
Eligibility Criteria
Inclusion
- Allergic rhinitis to grass pollen, more than 3 mm reaction at skin prick test for grass, age between 18 and 40 years.
Exclusion
- Uncontrolled asthma.
- Severe asthma with post bronchodilator test forced expiratory volume at 1 second less than 70% of expected.
- Severe co morbidity. Allergy to Fenol or Aluminium hydroxid.
- Any autoimmune diseases. Treatment with beta blocking medicine.
- Any heart diseases.
- Severe arterial hypertension. Kidney failure.
- Known malignancy. Known pregnancy.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT02255604
Start Date
August 1 2013
End Date
February 1 2017
Last Update
May 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lungemedicinsk Forskningsafdeling. Aarhus University Hospital
Aarhus, Denmark, 8000